Guidance. Clarity. Direction.

Carter, DeLuca & Farrell LLP, a leader in intellectual property law, provides cost-effective services to clients from around the world, protecting innovations in a wide range of technologies.

Throughout the phases of product or brand development, we form a critical part of our clients’ development teams to provide preparation, prosecution and clearance services to maximize protection while navigating through freedom-to-operate challenges. We also provide extensive IP due diligence services and IP asset assimilation to help our clients achieve their business objectives.

Search Attorneys

Events

Aug
5 – 6
2019
Design Rights Boot Camp AttendingJoin Carter, DeLuca & Farrell LLP Partner Pina Campagna and the American Intellectual Property Law Association (AIPLA) for the Design Rights Boot Camp on...
Sep
19 – 22
2019
27th IAKL Annual Conference AttendingCarter DeLuca Partner Chul-Woo Lee will be attending the 27th Annual International Association of Korean Lawyers (IAKL) Conference from September 19, 2019...

CAFC Update

UCB, INC. v. WATSON LABORATORIES INC. June 24, 2019

UCB owns U.S. Patent Nos. 6,884,434 and 8,232,414, claiming a transdermal therapeutic system comprising rotigotine, a drug used for the treatment of Parkinson’s disease, and a polymorph of rotigotine. The FDA approved UCB’s rotigotine transdermal patches, and UCB has been selling the product under the brand name Neupro. Actavis filed an Abbreviated New Drug Application...

UCB owns U.S. Patent Nos. 6,884,434 and 8,232,414, claiming a transdermal therapeutic system comprising rotigotine, a drug used for the treatment...

GAME AND TECHNOLOGY CO., LTD. v. ACTIVISION BLIZZARD INC June 21, 2019

UCB owns U.S. Patent Nos. 6,884,434 and 8,232,414, claiming a transdermal therapeutic system comprising rotigotine, a drug used for the treatment...

MAYNE PHARMA INTERNATIONAL PTY v. MERCK SHARP & DOHME CORP.

Mayne Pharma appeals from the final written decision of the U.S. Patent and Trademark Office Patent Trial and Appeal Board (“the Board”) in an inter partes review, concluding that certain claims of U.S. Patent 6,881,745 relating to pharmaceutical compositions of azole antifungal drugs are unpatentable as anticipated or obvious. In response to Mayne’s argument that the Board should not...

Mayne Pharma appeals from the final written decision of the U.S. Patent and Trademark Office Patent Trial and Appeal Board (“the Board”) in...